Efficacy and toxicity of BOPP and LOPP chemotherapy for the treatment of relapsed canine lymphoma

• Published in: Veterinary & comparative oncology Vol. 4; no. 1; pp. 21 - 32
• Main Authors: LeBlanc, A.K, Mauldin, G.E, Milner, R.J, LaDue, T.A, Mauldin, G.N, Bartges, J.W
• Format: Journal Article
• Language: English
• Published: Oxford, UK; Malden, USA Oxford, UK; Malden, USA : Blackwell Publishing Ltd 01-03-2006; Blackwell Publishing Ltd
• Subjects: adverse effects; alkylating agents; antineoplastic agents; BOPP chemotherapy; canine; carmustine; chemotherapy; clinical trials; dog diseases; dogs; drug evaluation; lomustine; LOPP chemotherapy; lymphoma; mechlorethamine; MOPP; relapse; rescue chemotherapy; sepsis; toxicity; veterinary drugs
• ISSN: 1476-5810; 1476-5829
• DOI: 10.1111/j.1476-5810.2006.00088.x

Mechlorethamine (Mustargen[superscript ®], Oncovin[superscript ®] (vincristine), procarbazine and prednisone (MOPP) chemotherapy is useful for relapsed canine lymphoma. This study evaluates the efficacy of MOPP after substitution of CCNU (lomustine, LOPP protocol) or BCNU (carmustine, BOPP protocol) for mechlorethamine in 60 dogs with relapsed lymphoma. Seven of 14 (50%) dogs treated with BOPP responded, for a median of 129.5 days for complete responders (range 9-354 days) and a median of 140 days for partial responders (range 4-276 days). Twenty-three of 44 (52%) dogs treated with LOPP responded for a median of 112 days for complete responders (range 48-250 days) and a median of 84.5 days for partial responders (range 69-290 days). Two dogs receiving a combination of LOPP and BOPP partially responded for 28 and 163 days, respectively. With BOPP chemotherapy, nine dogs (20.5%) and seven dogs (50%) had one or more episodes of Grade II or higher neutropenia and thrombocytopenia, respectively. Seven dogs (50%) had one or more episodes of Grade II or higher gastrointestinal toxicity. While receiving LOPP chemotherapy, 28 dogs (63.6%) and 17 dogs (38.6%) had one or more episodes of Grade II or higher neutropenia and thrombocytopenia, respectively. Seventeen dogs (38.6%) had one or more episodes of Grade II or higher gastrointestinal toxicity. Overall, there were 17 non-fatal treatment-related episodes of sepsis requiring hospitalization. Eight dogs (13%) died or were euthanized because of treatment-related sepsis and/or chemotherapy-related complications. Severe haematologic toxicity, coupled with the improved response duration observed in dogs receiving reduced doses during B/L-OPP rescue, underscores the need for protocol optimization.